Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2
Description
CONCLUSIONS: B-cell-depleting treatment was associated with a higher risk of COVID-19, higher rates of hospitalization, and ICU admission, suggesting this therapy carries a higher risk of severe infection in POMS and related disorders.
